N
GENB

Nuveen’s Generate Biomedicines GENB Stock Holding History

Nuveen’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$750K Buy
+44,470
New +$606K ﹤0.01% 3090

Other funds holding GENB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Nuveen's GENB Position: Q2 2026 in Review

Nuveen opened a new position in Generate Biomedicines (GENB) in Q2 2026: 44,470 shares worth $750K. The stake represents ﹤0.01% of the portfolio and ranks #3090 among its holdings.

30 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • Nuveen held 44,470 shares of Generate Biomedicines worth $750K as of Q2 2026.
  • Generate Biomedicines was a new Nuveen position in Q2 2026.
  • Generate Biomedicines made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3090 holding.
  • 30 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.